Quantcast

Latest Avastin Stories

2009-03-10 07:00:00

However, Off-Label Use of Avastin Will Take Market Share Away from Lucentis from 2012 to 2017, According to a New Report from Decision Resources WALTHAM, Mass., March 10 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that robust annual 17 percent growth in the age-related macular degeneration (AMD) market through 2012 will be driven primarily by expanding use of Genentech/Novartis Ophthalmics'...

2009-03-09 07:00:00

A Drug That Improves Survival, When Added to Temodar/Temodal, Would Earn a 65 Percent Patient Share in the U.S.

2009-01-26 07:00:00

New data demonstrates that Angiolix has similar efficacy to Avastin alone and in combination with other chemotherapeutics, with potentially less side-effects; study validates results seen in Previous Breast Cancer Model DALLAS, Jan. 26 /PRNewswire-FirstCall/ -- ACCESS PHARMACEUTICALS, INC.

2008-12-08 07:00:00

Generic Erosion Will Reduce Sales of Schering-Plough's Temodar/Temodal, the Current Market Leader, According to a New Report from Decision Resources WALTHAM, Mass., Dec.

2008-11-19 12:18:21

A drug touted as a safer, gentler way to treat cancer increases the risk of blood clots, a U.S.

2008-11-04 09:00:30

Genentech, a biotechnology company, has submitted a supplemental biologics license application to the FDA for Avastin as a therapy for people with previously treated glioblastoma.

2008-11-03 09:00:06

Genentech, Inc. (NYSE:DNA) today announced that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Avastin(R) (bevacizumab) as a therapy for people with previously treated glioblastoma.

2008-10-20 12:00:31

Genentech, a biotechnology company, has announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project that an ongoing Phase III study of Avastin plus chemotherapy in patients with early-stage colon cancer will continue as planned.

2008-10-20 03:00:08

Genentech, Inc. (NYSE:DNA) today announced that it has been informed by the National Surgical Adjuvant Breast and Bowel Project (NSABP) that an ongoing Phase III study (NSABP C-08) of Avastin(R) (bevacizumab) plus chemotherapy in patients with early-stage colon cancer will continue as planned.


Word of the Day
bawbee
  • A coin originally worth six pennies Scots, and later three; held equivalent to an English halfpenny.
  • (in plural) Money; cash.
Related